University College London
UCL is a multi-faculty university in London and receives the highest share of any UK university of the UK Government’s investment fund. UCL is also one of the leading recipients of EC funds, currently holding over 350 funded projects, contributing to an annual incurred expenditure of 30 million Euros of European Union funds. UCL has recently invested more than £250 million into state-of-the art infrastructure, facilitating cutting edge research across a broad range of disciplines. UCL’s total annual research income stands at an impressive £717.4m. The research strategy of UCL is oriented around a number of grand challenges explored by interdisciplinary centres.
Prof. Dr. Anthony Schapira
Prof. Dr. Anthony Schapira, DSc, FRCP, FMedSci is Head of Department of Clinical Neurosciences at the UCL Institute of Neurology.
He is a clinical neuroscientist with special expertise in mitochondrial dysfunction and is a Parkinson disease (PD) specialist. His areas of interest include the molecular pathogenesis of PD, particularly with reference to the contribution of mitochondrial and lysosomal abnormalities to PD. He has published widely on PD and more recently on the contribution of GBA1 mutations and lysosomal dysfunction in PD.
He will be closely involved in WP1, collaborating with University Luebeck to recruit patient samples for biochemical study to define the phenotype of primary and secondary mitochondrial abnormalities related to the cause of Parkinson disease.
Ruth-Mary deSouza is a clinician undertaking a PhD in Professor Schapira's lab.
Dr. Philip Campbell
Dr. Philip Campbell is a clinical fellow undertaking a PhD in Professor Schapira’s lab. His work in the project will contribute to the generation of genetically and phenotypically stratified PD cohorts and biomaterials in WP1 by investigating mitochondrial dysfunction in monogenic PD patients.
John Harvey is a Research Assistant working at the UCL Institute of Neurology.
He will co-ordinate patient recruitment in the UK, undertaking clinical assessments and genetic analysis of the cohort to support WP1. John studied Neuroscience MSc at The University of Sheffield, and has research interests in mitochondrial dysfunction in PD, early-onset PD and neurogenetics.
Emmeline Brown is a research assistant at the department of clinical & movement neurosciences at the UCL Institute of Neurology.
She specialises in genetic characterisation of Parkinson's disease patient cohorts and data analysis and will be involved in WP1.